Use of muscle relaxants in nonspecific lower back pain

DOI: https://doi.org/10.29296/25877305-2018-09-03
Download full text PDF
Issue: 
9
Year: 
2018

O. Kotova(1), Candidate of Medical Sciences; A. Artemenko(2), MD; E. Akarachkova(1), MD; A. Belyaev(3) 1-International Society «Stress under Control», Moscow 2-I.M. Sechenov First Moscow State Medical University (Sechenov University) 3-N.V. Sklifosovsky Research Institute of Emergency Care, Moscow

The priority in the management of a patient with back pain is its earliest possible relief. It is important to involve the patient in a set of remedial and rehabilitation treatments and to prevent chronic pain syndrome. Factors, such as pain intensity and duration, concomitant diseases, and ongoing therapy tolerability, play a crucial role in the choice of therapy. Muscle relaxants can alleviate or even eliminate excessive muscle tension. Their co-administration with nonsteroidal anti-inflammatory drugs makes it possible to lower the dosage of the latter and the risk of side effects.
Keywords: 
neurology
therapy
lower back pain
nonsteroidal anti-inflammatory drugs
muscle relaxants
baclofen

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kelsey J., White A. Epidemiology and impact of low back pain // Spine. – 1980; 5 (2): 133–9. DOI: 10.1097/00007632-198003000-00007.
  2. Vos T., Flaxman A., Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. – 2012; 380 (9859): 2163–96.
  3. Hoy D., Bain C., Williams G. et al. A systematic review of the global prevalence of low back pain // Arthritis Rheum. – 2012; 64 (6): 2028–37.
  4. Machado G., Maher C., Ferreira P. et al. Can Recurrence After an Acute Episode of Low Back Pain Be Predicted? // Phys. Ther. – 2017; 97 (9): 889–95. DOI: 10.1093/ptj/pzx067.
  5. Hoy D., Brooks P., Blyth F. et al. The Epidemiology of low back pain // Best Pract. Res. Clin. Rheumatol. – 2010; 24 (6): 769–81. DOI: 10.1016/j.berh.2010.10.002.
  6. Wertli M., Rasmussen-Barr E., Weiser S. et al. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review // Spine. – 2014; 14 (5): 816–36.
  7. Boer M., Struys M., Versteegen G. Pain-related catastrophizing in pain patients and people with pain in the general population // Eur. J. Pain. – 2012; 16 (7): 1044–52.
  8. Wieser S., Horisberger B., Schmidhauser S. et al. Cost of low back pain in Switzerland in 2005 // Eur. J. Health Econ. – 2011; 12 (5): 455–67.
  9. Davies C., Nitz A., Mattacola C., Kitzman P. et al. Practice patterns when treating patients with low back pain: a survey of physical therapists // Physiother. Theor. Pract. – 2014; 30 (6): 399–408.
  10. Dagenais S., Caro J., Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally // Spine J. – 2008; 8 (1): 8–20.
  11. Deyo R., Weinstein J. Low back pain // N. Engl. J. Med. – 2001; 344: 363–70. DOI: 10.1056/NEJM200102013440508.
  12. Croft P., Macfarlane G., Papageorgiou A. et al. Outcome of low back pain in general practice: a prospective study // BMJ. – 1998; 316: 1356–9.
  13. Dillingham T. Evaluation and management of low back pain: and overview // State Art Rev. – 1995; 9 (3): 559–74.
  14. Kotova O.V., Akarachkova E.S. Bol' v spine: epidemiologija, etiologija, lechenie // Consilium Medicum. – 2017; 2 (3): 43–7.
  15. Kotova O.V., Akarachkova E.S., Danilov A.B. Voprosy dlitel'noj terapii bolevyh sindromov // Rus. med. zhurn. – 2015; 23 (30): 16–8.
  16. Kotova O.V., Akarachkova E.S. Nezhelatel'nye javlenija nesteroidnyh protivovospalitel'nyh preparatov: vozmozhnye varianty vyhoda iz situatsii // Consilium Medicum. – 2017; 2 (2): 85–90.
  17. Kotova O.V. NPVP: v poiskah zolotoj serediny – sootnoshenie bezopasnost'/effektivnost' // Sprav. poliklin. vracha. – 2013; 1: 15–8.
  18. Walshe J., Venuto R. Acute oliguric renal failure induced by indomethacin: possible mechanism // Ann. Intern. Med. – 1979; 91: 47–9.
  19. Cannon P. Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs // Am. J. Med. – 1986; 81: 123–32.
  20. Bombardier C., Laine L., Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis // N. Engl. J. Med. – 2000; 343: 1520–8.
  21. Varga Z., Sabzwari S., Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue // Cureus. – 2017; 9 (4): e1144. DOI: 10.7759/cureus.1144.
  22. Strom B., Carson J., Schinnar R. et al. Nonsteroidal anti-inflammatory drugs and neutropenia // Arch. Intern. Med. – 1993; 153: 2119–22.
  23. Van Tulder M., Touray T., Furlan A. et al. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration // Spine. – 2003; 28 (17): 1978–92. DOI: 10.1097/01.BRS.0000090503.38830.AD.
  24. Van Tulder M., Becker A., Bekkering T. et al. European guidelines for the management of acute nonspecific low back pain in primary care // Eur. Spine J. – 2006; 15 (2): 169–91.
  25. Liu P., Guo W., Zhao X. et al. Intrathecal baclofen, a GABAB receptor agonist, inhibits the expression of p-CREB and NR2B in the spinal dorsal horn in rats with diabetic neuropathic pain // Can. J. Physiol. Pharmacol. – 2014; 92 (8): 655–60.
  26. Huang D., Huang S., Peers C., et al. GABAB receptors inhibit low-voltage activated and high-voltage activated Ca2+ channels in sensory neurons via distinct mechanisms // Biochem. Biophys. Res. Commun. – 2015; 465 (2):188–93.
  27. Narendran R., Duarte R., Valyi A. et al. The needfor and provision of intra the cal baclofen therapy for the management of spasticity in England: an assessment of the Hospital Episode Statistics database // BMJ Open. – 2015; 5 (6): e007517.
  28. Dapas F., Hartman S., Martinez L. et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo // Spine (PhilaPa 1976). – 1985; 10 (4): 345–9.
  29. Zaringhalam J., Manaheji H., Rastqar A. et al. Reduction of chronic non-specific low back pain: a randomised controlled clinical trial on acupuncture and baclofen // Chin. Med. – 2010; 5: 15. DOI: 10.1186/1749-8546-5-15.
  30. Deyo R. Comparative validity of the sickness impact profile and shorter scales for functional assessment in low-back pain // Spine. – 1986; 11 (9): 951–4. DOI: 10.1097/00007632-198611000-00017.
  31. Weiner D., Perera S., Rudy T. et al. Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: A randomized controlled trial // Pain. – 2008; 140 (2): 344–57. DOI: 10.1016/j.pain.2008.09.005.
  32. Konsensus po vedeniju patsientov s bol'ju v spine dlja terapevtov i vrachej obschej praktiki poliklinik. Pod red. N.N. Jahno, A.L. Vertkina, M.L. Kukushkina, V.A. Parfenova, A.E. Karateeva / M., 2017.